Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome--11beta-hydroxysteroid dehydrogenase type 1.
Stewart
Paul M
PM
Division of Medical Sciences, Institute of Biomedical Research, Medical School, University of Birmingham.
D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000273:Adipose Tissue / Q000201:enzymology*; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D003480:Cushing Syndrome / Q000150:complications / Q000201:enzymology*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008099:Liver / Q000201:enzymology*; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology
D015415:Biomarkers; D005938:Glucocorticoids; D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1